Houston Zoo Partners with BlueSprig to Enhance Inclusivity for Families with Autism
30. Oktober 2024 11:09 ET
|
BlueSprig Pediatrics, Inc.
HOUSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- In a groundbreaking initiative aimed at fostering inclusivity, the Houston Zoo has partnered with BlueSprig Pediatrics, Inc. (BlueSprig) to create a more...
BlueSprig Sponsors Armani Williams, the First Professional Driver in NASCAR Openly Diagnosed with Autism Spectrum Disorder
22. Oktober 2024 10:21 ET
|
BlueSprig Pediatrics, Inc.
MIAMI, Oct. 22, 2024 (GLOBE NEWSWIRE) -- BlueSprig Pediatrics, Inc. (BlueSprig), a leading provider of Applied Behavior Analysis (ABA) therapy services for children with autism, today announces it...
Lighthouse Autism Center Announces Expansion of ABA Services in Iowa
24. September 2024 09:00 ET
|
Lighthouse Autism Center
Lighthouse Autism Center is expanding its ABA services with a new center in Cedar Rapids, IA, set to open in late 2024. This will be their sixth IA center.
VR Helps Children with Autism Develop Social, Communication Skills, New Research Shows
23. September 2024 09:00 ET
|
BlueSprig Pediatrics, Inc.
HOUSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BlueSprig Pediatrics, Inc. (BlueSprig), a leader in Applied Behavior Analysis (ABA) therapy for children diagnosed with Autism Spectrum Disorder (ASD),...
Key Highlights of Lighthouse Fusion
27. August 2024 09:00 ET
|
Lighthouse Autism Center
Lighthouse Autism Center expands its speech therapy program with more dually certified SLPs and BCBAs, offering better outcomes for children with autism.
Lighthouse Autism Center Partners with Local Government Officials to Highlight Autism Services and Community Impact
16. August 2024 09:00 ET
|
Lighthouse Autism Center
Lighthouse Autism Center partners with local officials to boost autism awareness and support, with visits in several cities to highlight services.
Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism
30. Juli 2024 08:05 ET
|
Yamo Pharmaceuticals
Yamo Pharmaceuticals announces positive topline results from Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
09. Juli 2024 07:00 ET
|
STALICLA
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9,...
Transforming Children's Lives: DP World's Aviv Clinics Dubai’s Revolutionary Youth Protocol
07. Juli 2024 21:00 ET
|
Aviv Clinics
DUBAI, United Arab Emirates, July 07, 2024 (GLOBE NEWSWIRE) -- At DP World's Aviv Clinics Dubai, the world’s most advanced brain and body performance clinic, we understand the heartache parents feel...
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
27. Juni 2024 07:10 ET
|
STALICLA
Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core...